Cargando…
Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy
BACKGROUND: Oncolytic virotherapy (OV) is an immunotherapy that incorporates viral cancer cell lysis with engagement of the recruited immune response against cancer cells. Pediatric solid tumors are challenging targets because they contain both an inert immune environment and a quiet antigenic lands...
Autores principales: | Ghonime, Mohammed G, Saini, Uksha, Kelly, Michael C, Roth, Justin C, Wang, Pin-Yi, Chen, Chun-Yu, Miller, Katherine, Hernandez-Aguirre, Ilse, Kim, Yeaseul, Mo, Xiaokui, Stanek, Joseph R, Cripe, Tim, Mardis, Elaine, Cassady, Kevin A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488720/ https://www.ncbi.nlm.nih.gov/pubmed/34599026 http://dx.doi.org/10.1136/jitc-2021-002939 |
Ejemplares similares
-
Systemic cellular viroimmunotherapy for canine high-grade gliomas
por: Cloquell, Ana, et al.
Publicado: (2022) -
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
por: Crespo-Rodriguez, Eva, et al.
Publicado: (2020) -
Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
por: Zhang, Bo, et al.
Publicado: (2021) -
CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model
por: Wang, Ruikun, et al.
Publicado: (2022) -
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
por: Bozhanova, Galabina, et al.
Publicado: (2022)